Quoin Pharmaceuticals, Ltd. (QNRX)
NASDAQ: QNRX · Real-Time Price · USD
4.450
+0.250 (5.95%)
At close: Jun 26, 2026, 4:00 PM EDT
4.342
-0.108 (-2.42%)
After-hours: Jun 26, 2026, 7:58 PM EDT
Quoin Pharmaceuticals Employees
As of December 31, 2025, Quoin Pharmaceuticals had 6 total employees, including 4 full-time and 2 part-time employees. The number of employees increased by 1 or 20.00% compared to the previous year.
Employees
6
Change (1Y)
1
Growth (1Y)
20.00%
Revenue / Employee
n/a
Profits / Employee
-$2,831,702
Market Cap
8.94M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 35 |
| Curis | 24 |
| Bolt Biotherapeutics | 23 |
| MetaVia | 8 |
| Ernexa Therapeutics | 7 |
| Immuron | 7 |
| Cadrenal Therapeutics | 5 |
| Kairos Pharma | 4 |
QNRX News
- 3 days ago - Quoin Pharmaceuticals announces conditional FDA approval for Qyleki brand name - TheFly
- 3 days ago - Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome - GlobeNewsWire
- 8 days ago - Quoin Pharmaceuticals completes establishment of subsidiary in Japan - TheFly
- 8 days ago - Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003 - GlobeNewsWire
- 10 days ago - Quoin reports positive pediatric data in Netherton Syndrome program - TheFly
- 10 days ago - Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program - GlobeNewsWire
- 11 days ago - Quoin Pharmaceuticals initiated with a Buy at ThinkEquity - TheFly
- 22 days ago - Quoin Pharmaceuticals granted Orphan Drug Designation for QRX003 in Japan - TheFly